Showing 5011-5020 of 7091 results for "".
- 23-Gene Expression Profiling Accurately Classifies Pediatric Melanocytic Lesionshttps://practicaldermatology.com/news/23-gene-expression-profiling-accurately-classifies-pediatric-melanocytic-lesions/2485549/A 23-gene expression profiling assay accurately distinguished benign nevi from melanoma in pediatric patients, according to “23-GEP Accurately Distinguishes Between Melanocytic Nevi and Melanoma in Pediatric Melanocytic Neoplasms,” a poster by Drazen Jukic, MD, et al presented as part of the “Bes
- Dupilumab Produces Early and Sustained Improvements in CSU Activityhttps://practicaldermatology.com/news/dupilumab-produces-early-and-sustained-improvements-in-csu-activity/2485548/Dupilumab produced early and sustained reductions in urticaria activity in patients with chronic spontaneous urticaria (CSU), according to “Dupilumab Provides Early and Sustained Improvement in Urticaria Activity in Patients With Chronic Spontaneous Urticaria,” a poster by Jonathan A. Bernstein,
- Arcutis Reports Positive Phase 2 Data for Infant Atopic Dermatitis Programhttps://practicaldermatology.com/news/arcutis-reports-positive-phase-2-data-for-infant-atopic-dermatitis-program/2485557/Arcutis Biotherapeutics reported positive topline results from the phase 2 INTEGUMENT-INFANT trial evaluating investigational ZORYVE® (roflumilast) cream 0.05% in infants aged 3 months to younger than 24 months with mild to moderate atopic dermatitis (AD).
- Study: Mycophenolate Mofetil Effective as First-Line Option for Juvenile Localized Sclerodermahttps://practicaldermatology.com/news/study-mycophenolate-mofetil-effective-as-first-line-option-for-juvenile-localized-scleroderma/2485505/A new study comparing methotrexate (MTX) and mycophenolate mofetil (MMF) suggests MMF may offer a comparable alternative with better patient-reported tolerability outcomes. Researchers analyzed data from 114 patients (MTX [n=68
- Arcutis Ends Kowa Promotional Partnership, Assumes Control of ZORYVE Promotionshttps://practicaldermatology.com/news/arcutis-ends-kowa-deal-assumes-full-control-of-zoryve-outreach/2485454/Arcutis Biotherapeutics has terminated its co-promotion agreement with Kowa Pharmaceuticals America, Inc. for ZORYVE® (roflumilast), effective January 23, 2026, according to a press relase from the company. Under the prior arran
- Sclerotic cGVHD Patients Show Higher Risk for Outcome Reporting Mismatchhttps://practicaldermatology.com/news/patient-reported-cgvhd-worsening-linked-to-mortality-in-sclerotic-disease/2485447/A new longitudinal cohort study published in JAMA Dermatology showed differences in frequency and importance of discordance between clinician-reported and patient-reported outcomes in cutaneous chronic graft-vs-host disease (cG
- Low-Dose Minocycline Superior in Treating Inflammatory Rosaceahttps://practicaldermatology.com/news/low-dose-minocycline-dfd-29-superior-in-treating-inflammatory-rosacea/2485398/New data presented at 2026 Winter Clinical Hawaii showed DFD-29, a modified low-dose oral minocycline 40 mg, significantly outperformed both placebo and doxycycline 40 mg in the treatment of inflammatory lesions in patients with moderate-to-severe rosacea.
- Study: Upadacitinib Reduces Inflammation Markers in ADhttps://practicaldermatology.com/news/study-upadacitinib-reduces-inflammation-markers-in-ad/2485380/Upadacitinib (UPA) treatment was associated with significant reductions in biomarkers of systemic inflammation in adults with moderate-to-severe atopic dermatitis (AD), according to a poster presented at Winter Clinical 2026 in Hawaii.
- TYK2 Inhibitor ICP-332 Demonstrates Efficacy, Safety in ADhttps://practicaldermatology.com/news/tyk2-inhibitor-icp-332-demonstrates-efficacy-safety-in-ad/2485331/A novel oral TYK2 inhibitor, ICP-332, demonstrated favorable safety and promising efficacy in a recent phase 2 randomized clinical trial for moderate to severe atopic dermatitis (AD). Researchers for the double-blind, placebo-co
- Swann Dermatology Partners Merges with Forefront Dermatologyhttps://practicaldermatology.com/news/swann-dermatology-partners-merges-with-forefront-dermatology-in-strategic-expansion-move/2485339/Swann Dermatology Partners (SDP), a multi-location practice based in Springfield, Missouri, announced that it has officially joined Forefront Dermatology, a nationwide dermatology network backed by private equity firm Partners Group.